Stem Cell Therapy Argentina's Regenerative Treatment Dosage Sets It Apart from 99% of Regenerative Medicine Institutes.

Blog written by Dr. Matias Fernandez Vina. Ceo of Stem Cell Therapy in Argentina.

In most medical treatments, dosage is critical to success and is never overlooked. However, in ortobiología and regenerative therapies, the 99% of the clinics you may go you have no idea of the dosage of PRP or Stem Cells Mesenchymal that you are injecting. You can verify this in any regenerative medical consultation by asking how many platelets or stem cells are being administered and will simply last a few tubes or tissue volume you get.. but the difficult the final dose of the product to be placed.

In recent years, the practices ortobiológicas advanced, have started to pay attention to the dosage of PRP. We have been driving for over 7 years.

Stem Cell Therapy in Argentina is part of the 1% of the clinics that dosed the biological products of regenerative medicine, both platelet-rich plasma, as cells mesenchymal stem cells from bone marrow and adipose tissue.

Stem Cell Therapy Argentina quantifies doses higher than 6 billion platelets for Platelet-Rich Plasma. This PRP is what we call "PRP Hiperconcentrado", and although many clinics to replicate this name, is registered by the regulator of records in Argentina, [PTO], under our brand, being a protocol 100% original by multiple injections.

The same thing happens with the cell therapy and stem cells mesenchymal expanded adipose tissue. Stem Cell Therapy of Argentina, offers injections of 100 million cells mesenchymal to the control of the degenerative osteoarthritis of the knee, shoulder and hip, and 20 million to tendons and ligaments.

Without a doubt, the success of the treatments that we have with patients, depend on what is achieved by the 1% of the clinics, such as Stem Cell Therapy, Argentina, protocols strictly prepared by staff that is dedicated 100% to the regenerative medicine and advanced therapies.

Share

Newsletter

Sign up to our newsletter and got all of our news by e-mail.

en_GB